MET signaling in colon cancer stem-like cells blunts the therapeutic response to EGFR inhibitors.
Open accessPublished version of a preprint
The DOI matches its Crossref record; 46 of the 47 references it cites were found in a registry or an index.
Abstract
Metastatic colorectal cancer remains largely incurable, although in a subset of patients, survival is prolonged by new targeting agents such as anti-EGF receptor (anti-EGFR) antibodies. This disease is believed to be supported by a subpopulation of stem-like cells termed colon cancer–initiating cell (CCIC), which may also confer therapeutic resistance. However, how CCICs respond to EGFR inhibition has not been fully characterized. To explore this question, we systematically generated CCICs through spheroid cultures of patient-derived xenografts of metastatic colorectal cancer. These cultures, termed “xenospheres,” were capable of long-term self-propagation in vitro and phenocopied the original patient tumors in vivo, thus operationally defining CCICs. Xenosphere CCICs retained the genetic determinants for EGFR therapeutic response in vitro and in xenografts; like the original tumors, xenospheres harboring a mutated KRAS gene were resistant to EGFR therapy, whereas those harboring wild-type RAS pathway genes (RASwt) were sensitive. Notably, the effects of EGFR inhibition in sensitive CCICs could be counteracted by cytokines secreted by cancer-associated fibroblasts. In particular, we found that the MET receptor ligand hepatocyte growth factor (HGF) was especially active in supporting in vitro CCIC proliferation and resistance to EGFR inhibition. Ectopic production of human HGF in CCIC xenografts rendered the xenografts susceptible to MET inhibition, which sensitized the response to EGFR therapy. By showing that RASwt CCICs rely on both EGFR and MET signaling, our results offer a strong preclinical proof-of-concept for concurrent targeting of these two pathways in the clinical setting. Cancer Res; 74(6); 1857–69. ©2014 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Luraghi et al. reported that HGF can bind to MET receptors and activate MAPK and AKT to induce cetuximab resistance in vitro [75].”
From Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies (2021) · cites this paper as [75]
In the citing paper
“Conditional medium (CM) from CAF can confer anti-EGFR resistance in CRC stem-cell-like cells, which may be wild-type MET activated by CAF-derived HGF [303].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [303]
In the citing paper
“Upregulated receptor tyrosine kinases (RTKs), including ERBB2, MET and IGF-1R, activate the PI3K/AKT axis or reactivate the ERK pathway independently of EGFR [73–76].”
From Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies (2021) · cites this paper as [75]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Glioma stem cells promote radioresistance by preferential activation of the DNA damage response
Bao, S., Wu, Q., McLendon, R. E., Hao, Y., Shi, Q., Hjelmeland, A. B., Dewhirst, M. W., Bigner, D. D., & Rich, J. N. (2006) · Nature · doi:10.1038/nature05236 · Cited by 6,379
Kalluri, R., & Zeisberg, M. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1877 · Cited by 4,538 · cited 1×
“Colorectal cancer–associated fibroblasts (CAF) are known to secrete several growth factors, cytokines, and chemokines (29, 30).”
BackgroundA human colon cancer cell capable of initiating tumour growth in immunodeficient mice
O’Brien, C. A., Pollett, A., Gallinger, S., & Dick, J. E. (2007) · Nature · doi:10.1038/nature05372 · Cited by 4,087 · cited 4×
“” Increasing evidence shows that colorectal cancer—as well as other tumors—contains such cells, more appropriately defined as cancer-initiating cells (CIC), to emphasize their distinctive operational property of driving clonal expansion in xenotransplantation assays (6, 7).”
BackgroundInfluentialIdentification and expansion of human colon-cancer-initiating cells
Ricci-Vitiani, L., Lombardi, D. G., Pilozzi, E., Biffoni, M., Todaro, M., Peschle, C., & De Maria, R. (2007) · Nature · doi:10.1038/nature05384 · Cited by 3,998 · cited 5×
“The quest for cells maintaining the genetic and histogenetic properties of the original tumors has led to tumor “spheres,” primary cultures established by a protocol initially set up for neural stem cells (38), and later successfully applied to several tumor tissues, including colorectal cancer (7, 11, 23, 24).”
BackgroundInfluentialA restricted cell population propagates glioblastoma growth after chemotherapy
Chen, J., Li, Y., Yu, T.-S., McKay, R. M., Burns, D. K., Kernie, S. G., & Parada, L. F. (2012) · Nature · doi:10.1038/nature11287 · Cited by 2,354
Creation of human tumour cells with defined genetic elements
Hahn, W. C., Counter, C. M., Lundberg, A. S., Beijersbergen, R. L., Brooks, M. W., & Weinberg, R. A. (1999) · Nature · doi:10.1038/22780 · Cited by 2,345 · cited 2×
“Weinberg, Whitehead Institute for Biomedical Research, Cambridge, Massachusetts, (18).”
BackgroundLee, J., Kotliarova, S., Kotliarov, Y., Li, A., Su, Q., Donin, N. M., Pastorino, S., Purow, B. W., Christopher, N., Zhang, W., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.03.030 · Cited by 2,311 · cited 3×
“Notably, tumor spheres retain the genetic make-up of the original cancer far more faithfully than standard cell lines (37); thus, regardless of their "stem" properties, they should be more suitable than cell lines to identify the mechanisms responsible for sensitivity and resistance to molecular cancer therapeutics.”
BackgroundEGFR Antagonists in Cancer Treatment
Ciardiello, F., & Tortora, G. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0707704 · Cited by 2,058
Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer
Misale, S., Yaeger, R., Hobor, S., Scala, E., Janakiraman, M., Liska, D., Valtorta, E., Schiavo, R., Buscarino, M., Siravegna, G., et al. (2012) · Nature · doi:10.1038/nature11156 · Cited by 1,889 · cited 1×
“This could be explained by the presence of (i) an excess EGF (20 ng/mL) that likely outcompeted the effective dose of the antibody (10 μg/mL) for binding the EGFR receptor extracellular domain (5, 27), and (ii) bFGF (10 ng/mL) that could compensate for EGFR inhibition in sustaining viability.”
BackgroundWnt activity defines colon cancer stem cells and is regulated by the microenvironment
Vermeulen, L., De Sousa E Melo, F., van der Heijden, M., Cameron, K., de Jong, J. H., Borovski, T., Tuynman, J. B., Todaro, M., Merz, C., Rodermond, H., et al. (2010) · Nature Cell Biology · doi:10.1038/ncb2048 · Cited by 1,804 · cited 1×
“Concerning colorectal cancer, it was previously shown that HGF can sustain the WNT self-renewal pathway (42, 43).”
Background
Cited by
Comprehensive review of targeted therapy for colorectal cancer
Xie, Y.-H., Chen, Y.-X., & Fang, J.-Y. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0116-z · Cited by 1,687
Spherical Cancer Models in Tumor Biology
Weiswald, L.-B., Bellet, D., & Dangles-Marie, V. (2015) · Neoplasia · doi:10.1016/j.neo.2014.12.004 · Cited by 1,141
“…Spheroids [40] Colospheres [43,44] Spheres [30,34,36,38,39] Tumorspheres [30] Oncospheres [34] Xenospheres (from patient tumor-derived xenografts) [176] Neurospheres (normal and malignant brain) [35,36] Mammospheres (normal and malignant breast) [37,38] Colon cancer spheres (colon cancer) [39]…”
BackgroundConsensus molecular subtypes and the evolution of precision medicine in colorectal cancer
Dienstmann, R., Vermeulen, L., Guinney, J., Kopetz, S., Tejpar, S., & Tabernero, J. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2016.126 · Cited by 1,021
Cancer Stem Cells (CSCs) in Drug Resistance and their Therapeutic Implications in Cancer Treatment
Phi, L. T. H., Sari, I. N., Yang, Y.-G., Lee, S.-H., Jun, N., Kim, K. S., Lee, Y. K., & Kwon, H. Y. (2018) · Stem Cells International · doi:10.1155/2018/5416923 · Cited by 994
“CAFs are known to secrete many different growth factors, cytokines, and chemokines, including hepatocyte growth factor (HGF), which activates the MET receptors to protect the CSCs from apoptosis in response to the cetuximab monotherapy targeting the EGFR in metastatic colorectal cancer [122].”
BackgroundCancer Stem Cells: Basic Concepts and Therapeutic Implications
Nassar, D., & Blanpain, C. (2016) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-012615-044438 · Cited by 869
Metadata
- Authors
- Luraghi, P., Reato, G., Cipriano, E., Sassi, F., Orzan, F., Bigatto, V., De Bacco, F., Menietti, E., Han, M., Rideout, W. M., Perera, T., Bertotti, A., Trusolino, L., Comoglio, P. M., & Boccaccio, C.
- Affiliations
- Janssen (Belgium) (BE)
- Authors' Affiliations: 1Institute for Cancer Research at Candiolo (IRCC), Center for Experimental Clinical Molecular Oncology; 2Department of Oncology, University of Torino, Candiolo, Torino, Italy; 3Aveo Oncology Inc., Cambridge, Massachusetts; and 4Janssen Research and Development, A Division of Janssen Pharmaceutica NV, Beerse, Belgium
- Corresponding author
- Comoglio, Paolo M.
- Boccaccio, Carla
- ORCID
- Venue
- Cancer Research
- Published
- 2014-03-13
- Volume
- 74
- Issue
- 6
- Pages
- 1857-1869
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W2148532468
- Cited by
- 146
- References
- 47
- Citations by year
- 2026: 4 · 2025: 6 · 2024: 8 · 2023: 7 · 2022: 10 · 2021: 23 · 2020: 12 · 2019: 12 · 2018: 14 · 2017: 15 · 2016: 11 · 2015: 16 · 2014: 8
- FWCI
- 8.05
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
- Funders
- Fondazione Umberto Veronesi
- Topics
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Mechanisms and Therapy
- Keywords
- C-MET signaling, EGFR inhibitors, metastatic colorectal cancer, treatment resistance, hepatocyte growth factor, cancer-associated fibroblasts, KRAS mutation, Ras signaling, patient-derived xenografts, combination therapy, MET inhibition
- MeSH terms
- Cetuximab, Animals, Antineoplastic Agents, Cell Survival, Colonic Neoplasms, Drug Synergism, Female, Humans, Mice, Transgenic, Tumor Cells, Cultured, Neoplastic Stem Cells, Signal Transduction, Mice, SCID, Mice, Inbred NOD, Hepatocyte Growth Factor, Spheroids, Cellular, Drug Resistance, Neoplasm, Proto-Oncogene Proteins c-met, Xenograft Model Antitumor Assays, Tumor Burden, Cell Proliferation, Mice, Antibodies, Monoclonal, Humanized, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: MET signaling in colon cancer stem-like cells blunts the therapeutic response to EGFR inhibitors. https://app.cochat.ai/papers/10.1158/0008-5472.can-13-2340-t
- The paper
- Luraghi, P., Reato, G., Cipriano, E., Sassi, F., Orzan, F., Bigatto, V., De Bacco, F., Menietti, E., Han, M., Rideout, W. M., Perera, T., Bertotti, A., Trusolino, L., Comoglio, P. M., & Boccaccio, C. (2014). MET signaling in colon cancer stem-like cells blunts the therapeutic response to EGFR inhibitors. Cancer Research. https://doi.org/10.1158/0008-5472.can-13-2340-t
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.